Shahrokh Z - Search Results

1

Challenges in the development of high protein concentration formulations.

Shire SJ, Shahrokh Z, Liu J. Shire SJ, et al. Among authors: shahrokh z. J Pharm Sci. 2004 Jun;93(6):1390-402. doi: 10.1002/jps.20079. J Pharm Sci. 2004. PMID: 15124199 Review.

2

Approaches to analysis of aggregates and demonstrating mass balance in pharmaceutical protein (basic fibroblast growth factor) formulations.

Shahrokh Z, Stratton PR, Eberlein GA, Wang YJ. Shahrokh Z, et al. J Pharm Sci. 1994 Dec;83(12):1645-50. doi: 10.1002/jps.2600831202. J Pharm Sci. 1994. PMID: 7891289

3

Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue.

Rubas W, Cromwell ME, Shahrokh Z, Villagran J, Nguyen TN, Wellton M, Nguyen TH, Mrsny RJ. Rubas W, et al. Among authors: shahrokh z. J Pharm Sci. 1996 Feb;85(2):165-9. doi: 10.1021/js950267+. J Pharm Sci. 1996. PMID: 8683442

4

Stability of alkoxycarbonylamidine prodrugs.

Shahrokh Z, Lee E, Olivero AG, Matamoros RA, Robarge KD, Lee A, Weise KJ, Blackburn BK, Powell MF. Shahrokh Z, et al. Pharm Res. 1998 Mar;15(3):434-41. doi: 10.1023/a:1011928415808. Pharm Res. 1998. PMID: 9563074

5

Chromatographic methods for quantitative analysis of native, denatured, and aggregated basic fibroblast growth factor in solution formulations.

Sluzky V, Shahrokh Z, Stratton P, Eberlein G, Wang YJ. Sluzky V, et al. Among authors: shahrokh z. Pharm Res. 1994 Apr;11(4):485-90. doi: 10.1023/a:1018946011652. Pharm Res. 1994. PMID: 8058602

6

Characterization, stability, and formulations of basic fibroblast growth factor.

Wang YJ, Shahrokh Z, Vemuri S, Eberlein G, Beylin I, Busch M. Wang YJ, et al. Among authors: shahrokh z. Pharm Biotechnol. 1996;9:141-80. doi: 10.1007/0-306-47452-2_2. Pharm Biotechnol. 1996. PMID: 8914191 Review. No abstract available.

7

Asparagine deamidation in recombinant human lymphotoxin: hindrance by three-dimensional structures.

Xie M, Shahrokh Z, Kadkhodayan M, Henzel WJ, Powell MF, Borchardt RT, Schowen RL. Xie M, et al. Among authors: shahrokh z. J Pharm Sci. 2003 Apr;92(4):869-80. doi: 10.1002/jps.10342. J Pharm Sci. 2003. PMID: 12661072

8

Mass spectrometry innovations in drug discovery and development.

Papac DI, Shahrokh Z. Papac DI, et al. Among authors: shahrokh z. Pharm Res. 2001 Feb;18(2):131-45. doi: 10.1023/a:1011049231231. Pharm Res. 2001. PMID: 11405282 Review.

9

Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.

Leong SR, DeForge L, Presta L, Gonzalez T, Fan A, Reichert M, Chuntharapai A, Kim KJ, Tumas DB, Lee WP, Gribling P, Snedecor B, Chen H, Hsei V, Schoenhoff M, Hale V, Deveney J, Koumenis I, Shahrokh Z, McKay P, Galan W, Wagner B, Narindray D, Hébert C, Zapata G. Leong SR, et al. Among authors: shahrokh z. Cytokine. 2001 Nov 7;16(3):106-19. doi: 10.1006/cyto.2001.0936. Cytokine. 2001. PMID: 11741351

10

Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity.

Koumenis IL, Shahrokh Z, Leong S, Hsei V, Deforge L, Zapata G. Koumenis IL, et al. Among authors: shahrokh z. Int J Pharm. 2000 Mar 30;198(1):83-95. doi: 10.1016/s0378-5173(99)00458-5. Int J Pharm. 2000. PMID: 10722953

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page